Key points are not available for this paper at this time.
The clinical trial met its primary objective demonstrating an acceptable safety profile of endobronchially administered autologous ADSCs-SVF. Our findings accelerate the rapidly expanded scientific knowledge and indicate a way towards future efficacy trials.
Τzouvelekis et al. (Mon,) studied this question.